نتایج جستجو برای: dacarbazine
تعداد نتایج: 1818 فیلتر نتایج به سال:
Before the recent developments in targeted [1–4] and immune therapies [5–7], the standard systemic treatment of metastatic melanoma was limited to chemotherapy, and in selected patients interlukin-2. These standards had not changed for over a decade, and dacarbazine was the reference systemic therapy against which others were compared, despite having never been compared with best supportive car...
Background: Nanotechnology is evolving in the field of cancer drug design and therapy. The ultrafine nanoparticles that have a size range 1-10nm are called Quantum Dots. ability to fluorescence has deemed quantum dots as suitable candidate for diagnostic imaging. Upon proper structural arrangement these can be engineered detect specifically cells deliver anticancer agents targeted site cell apo...
Melanoma is highly heterogeneous type of skin cancer originated from transformed melanocytes. Quiescent melanoma cells recognized within various populations as residing temporarily in G0 phase a cell cycle. Our study revealed that both dacarbazine or BRAF V600E inhibitor vemurafenib treatment vitro induced not only apoptosis but transition proliferative However, G0-positive could represent quie...
Accesion For NTIS CRA&I DTIC TAB Unannounced Justification,^^-,
Mutations of the serine/threonine-protein kinase BRAF protein are found in 80% of melanomas. Vemurafenib (Zelboraf, Genentech/Daiichi Sankyo), a specific inhibitor of BRAF, was approved by the FDA for metastatic melanoma in August 2011. Dabrafenib (GlaxoSmithKline, GSK 2118436), tested in the BREAK-2 trial, demonstrated a 59% confirmed response rate with a median progression-free survival (PFS)...
Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours. We investigated the therapeutic benefit of temozolomide (TMZ), an oral alternative to dacarbazine, in patients with MPP. This is a retrospective study of consecutive patients wi...
BACKGROUND O(6)-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or temozolomide. PATIENTS AND METHODS We evaluated the prognostic and predictive value of MGMT methylation testing both in tumor and cell-free circulating DNA (cfDNA) from plasma samples using an ultra-sensitive two-step digita...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید